Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts.
Sign Up to like & getrecommendations! Published in 2018 at "Drug discovery today"
DOI: 10.1016/j.drudis.2018.02.012
Abstract: Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B… read more here.
Keywords: car cell; cell therapies; term; glaring safety ... See more keywords